Current status of cell-based interventions in Japan

Misao Fujita; Taichi Hatta; Kazuki Ide

doi:10.1016/j.stem.2022.08.003

Current status of cell-based interventions in Japan

Cell Stem Cell. 2022 Sep 1;29(9):1294-1297. doi: 10.1016/j.stem.2022.08.003.

Authors

Misao Fujita¹, Taichi Hatta², Kazuki Ide³

Affiliations

¹ Uehiro Research Division for iPS Cell Ethics, Center for iPS Cell Research and Application (CiRA), Kyoto University, Sakyo-ku, Kyoto 606-8507, Japan; Institute for the Advanced Study of Human Biology (WPI-ASHBi), KUIAS, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan. Electronic address: misao-fujita@cira.kyoto-u.ac.jp.
² Graduate School of Public Health, Shizuoka Graduate University of Public Health, Aoi-ku, Shizuoka 420-0881, Japan.
³ Division of Scientific Information and Public Policy, Center for Infectious Disease Education and Research, Osaka University, Suita, Osaka 565-0871, Japan; Research Center on Ethical, Legal and Social Issues, Osaka University, Suita, Osaka 565-0871, Japan.

PMID: 36055190
DOI: 10.1016/j.stem.2022.08.003

Abstract

The Act on the Safety of Regenerative Medicine regulates cell-based interventions in Japan. Recent revisions to the law require disclosure of explanatory and consent materials for interventions seeking approval. In this Forum, we present an updated analysis of the status and challenges facing the Japanese regulatory framework.

MeSH terms

Japan
Regenerative Medicine*